Percutaneously-quantified advanced glycation end-products (AGEs) accumulation associates with low back pain and lower extremity symptoms in middle-aged low back pain patients
Percutaneously-quantified advanced glycation end-products (AGEs) accumulation associates with low back pain and lower extremity symptoms in middle-aged low back pain patients
复制标题
DOI：
10.1016/j.jocn.2020.12.005
复制
发表时间：
2021-02-01
影响因子：
2
通讯作者：
Ohtori, Seiji
中科院分区：
文献类型：
--
作者：
Umimura, Tomotaka;Orita, Sumihisa;Ohtori, Seiji
晚期糖基化终末产物(AGEs)已被报道为衰老和代谢性疾病的一个可能的生物标志物；然而，它在这些疾病的临床进展中的作用尚不清楚。我们的目的是评估年龄与下腰痛(LBP)患者的临床症状和合并症的关系。这项前瞻性队列研究纳入了636名LBP患者。他们接受了皮肤自发荧光定量年龄(QAGE)分析，并测量了他们的临床症状和并发症，如糖尿病、血液透析治疗的肾功能衰竭和骨质疏松症。使用视觉模拟评分(VAS)评估LBP、下肢疼痛和麻木。在有任何共病的受试者中，所测得的qAGE显著较高。年龄与qAGE呈显著正相关。肢体麻木的QAGE与VAS呈正相关。此外，在50岁以下的LBP患者中，qAGE与LBP、下肢疼痛和麻木的VAS呈正相关。总之，通过皮肤自发荧光测量的qAGE在伴有糖尿病和透析的LBP患者以及骨质疏松症患者中显著升高。此外，在50岁以下的患者中，qAGE显示出作为LBP、下肢疼痛和麻木的生物标记物的潜力。如果累积年龄是在年轻时确定的，研究人员应该警惕骨质疏松症的发展和以后生活中与LBP相关的临床症状。(C)2020爱思唯尔有限公司。保留所有权利。
Advanced glycation end-products (AGEs) have been reported as a possible biomarker of ageing and metabolic diseases; however, its role in the clinical progression of these diseases remains unclear. We aimed to evaluate how AGEs are associated with clinical symptoms and comorbidities in lower back pain (LBP) patients. This prospective cohort study enrolled 636 LBP patients. They were subjected to quantified AGE (qAGE) analysis using skin autofluorescence, and their clinical symptoms and comorbidities, such as diabetes, renal failure with haemodialysis treatment, and osteoporosis, were measured. LBP, lower extremity pain, and numbness were evaluated using a visual analogue scale (VAS). The measured qAGE was significantly higher in subjects with any comorbidity. Age also showed a strong positive correlation with qAGE. qAGE and VAS for leg numbness were positively correlated. Furthermore, in LBP patients under 50-years-old, qAGE was positively correlated with VAS for LBP, lower extremity pain, and numbness. In conclusion, qAGE, as measured by skin autofluorescence measurement, was significantly higher in LBP patients with diabetes and dialysis, as well as in osteoporosis patients. Furthermore, qAGE showed potential as a biomarker for LBP, lower extremity pain, and numbness in patients under 50-years-old. If accumulated AGEs are identified at a young age, researchers should be vigilant for the development of osteoporosis and LBP-related clinical symptoms later in life. (C) 2020 Elsevier Ltd. All rights reserved.